Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00092235 · ClinicalTrials.gov registry record

Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease

A clinical trial of Chronic Graft vs. Host Disease, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
650
Enrollment target
1
Study location

NCT00092235: Recruiting study of Chronic Graft vs. Host Disease, sponsored by National Cancer Institute (NCI).

NCT00092235 is a study of Chronic Graft vs. Host Disease that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 650 participants, above the 17-participant average among 3 other Chronic Graft vs. Host Disease trials with a reported enrollment target (3724% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00092235, a study of Chronic Graft vs. Host Disease, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
650 participants
Enrollment target
1
Study location

Study Summary

Background: * Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT). It is characterized by immune dysregulation, immunodeficiency, impaired organ function, and decreased survival. * Each year about 8000 patients receive allogeneic hematopoietic stem cell transplant (alloHSCT) in North America and about 50% of patients who are transplanted develop cGVHD. * Chronic GVHD is also a disorder that simultaneously affects many organ systems in highly variable fashion and requires complex and coordinated medical management by multiple medical specialties. There is an urgent need for progress in understanding and effective treatments for cGVHD as it is one of the most serious complications of cancer therapy and hematopoietic stem cell transplantation. Objectives: * To establish a multidisciplinary clinic infrastructure for study of the pathogenesis and natural history of cGVHD. * To prospectively identify clinical and biological prognostic markers in patients with cGVHD * To develop clinically relevant cGVHD grading scales * To identify novel biological characteristics of cGVHD and to describe them in the context of clinical history and presentation * To identify potential clinical and biological markers of cGVHD activity * To improve understanding of the biology of cGVHD-associated graft-versus-tumor effects * To identify potential patients for cGVHD treatment protocols at the NCI and NIH Eligibility: -Patients age 1 and older referred by the primary transplant physician for the evaluation of chronic graft-versus-host disease independent of underlying diagnosis. Design: * Patient undergoes initial clinical and laboratory multispecialty work-up at the NCI cGVHD clinic. * Minimally invasive biopsies and rarely, deep tissue biopsy may be obtained to confirm the diagnosis and/or rule-out other pathologic process (in adults only). * Long tem data col

Primary Outcome

Patient evaluations resulting in collection of data via several medical specialties; data will be examined individually and against clinical outcomes.

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 650 participants
Start Date 2004-10-26
National Cancer Institute (NCI)

3,257 total trials

What NCT00092235 shows while recruiting

NCT00092235 is an observational study that tracks outcomes without assigning an intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, above the 17-participant average among 3 other Chronic Graft vs. Host Disease trials with a reported enrollment target (3724% higher).

The record links to 1 condition, with Chronic Graft vs. Host Disease appearing as the primary indexed condition, and to 0 interventions.

NCT00092235 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00092235 about?

NCT00092235 is a clinical study titled "Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease". Background: * Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT). It is characterized by immune dysregulation, immunodeficiency, impaired organ function, and decreased surv...

What is the current status of trial NCT00092235?

This trial is currently recruiting. The enrollment target is 650 participants. The study started on 2004-10-26.

What conditions does trial NCT00092235 study?

This clinical trial studies the following conditions: Chronic Graft vs. Host Disease.

Who is sponsoring clinical trial NCT00092235?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00092235 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Graft vs. Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02934477 · 650 participants

    Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

  • NCT04579120 · 650 participants

    Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

  • NCT04875702 · 650 participants · Phase 4

    Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

  • NCT05046600 · 650 participants

    Registry of Arthrex Hand and Wrist Products

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00092235, the US trial registry maintained by the National Library of Medicine. NCT00092235 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.